Charles River expects hit of up to $215M from COVID-19

Charles River Labs is revising down its guidance by a maximum of $215 million as it warns the second quarter will see “a significant impact on the research models and services revenue growth rate.”

Unlike a number of its CRO peers, Charles River is not pulling its guidance completely, but said in its first quarter-report "the impact from the COVID-19 pandemic is expected to reduce 2020 revenue by approximately $135 to $215 million,” and it has revised its guidance accordingly.